The tax bill passed by the House and Senate still hasn’t been signed by President Trump. But one blue chip company, FedEx, is already touting the potential for a nearly $1.5 billion increase in annual profits due to lower corporate taxes.
FedEx reported its latest quarterly results after the closing bell Tuesday, before the Senate voted to approve the bill.
But the shipping giant told investors in its earnings release that its annual profits for fiscal 2018 could increase by $4.40 to $5.50 a share, mainly due to a change in how it values deferred tax liabilities as well as the cut in the corporate tax rate to 21%.
The lower tax rate on its own will lead earnings to be as much as $1 share higher, FedEx said.
FedEx has about 268.2 million total shares outstanding. So a possible $5.50 per share boost from lower taxes would translate to a $1.48 billion bump in annual earnings. Shares of FedEx (FDX) rose more than 3% on the news, hitting an all-time high.
Top 10 Blue Chip Stocks To Invest In Right Now: Internet Gold Golden Lines Ltd.(IGLD)
Advisors’ Opinion:
- [By Max Byerly]
Media stories about Internet Gold Golden Lines (NASDAQ:IGLD) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Internet Gold Golden Lines earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the technology company an impact score of 47.7616640405736 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Top 10 Blue Chip Stocks To Invest In Right Now: Archrock, Inc.(AROC)
Advisors’ Opinion:
- [By ]
As it happens, I am familiar with about half of these stocks. Archrock (Nasdaq: AROC), Qualcomm (Nasdaq: QCOM), Schlumberger (NYSE: SLB, and Trinity Industries (NYSE: TRN) are all interesting names that I’ve either owned in the past or have written about recently over at High-Yield Investing.
- [By Max Byerly]
COPYRIGHT VIOLATION NOTICE: “Bailard Inc. Has $381,000 Holdings in Archrock Inc (AROC)” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4150167/bailard-inc-has-381000-holdings-in-archrock-inc-aroc.html.
- [By Ethan Ryder]
Archrock (NYSE:AROC) posted its quarterly earnings data on Tuesday. The energy company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02, Briefing.com reports. The firm had revenue of $233.20 million during the quarter, compared to analysts’ expectations of $232.15 million. Archrock had a net margin of 6.32% and a return on equity of 2.49%. The business’s revenue was up 11.6% compared to the same quarter last year.
- [By Ethan Ryder]
News stories about Archrock (NYSE:AROC) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Archrock earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the energy company an impact score of 47.3449329112104 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Top 10 Blue Chip Stocks To Invest In Right Now: OncoCyte Corporation(OCX)
Advisors’ Opinion:
- [By Jon C. Ogg]
OncoCyte Corp. (NYSE: OCX) was started as Overweight with a $6 price target (versus a $3.84 close) at Piper Jaffray. It has a 52-week range of $1.10 to $6.92 and a market cap of only $191 million.
- [By Money Morning News Team]
You only have to review the one-week gains of some of the top penny stocks to see how much investors can benefit. The top performer recently, OncoCyte Corp. (NYSE: OCX), skyrocketed almost 160% on the week. Yet it can still be purchased at only $4.98 per share.
- [By Lisa Levin]
Losers
Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
Arcadia Biosciences, Inc. (N
Top 10 Blue Chip Stocks To Invest In Right Now: Israel Chemicals Shs(ICL)
Advisors’ Opinion:
- [By Stephan Byrd]
Israel Chemicals (NYSE:ICL) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
Kingstone Companies (NASDAQ:KINS) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Israel Chemicals (ICL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Get a free copy of the Zacks research report on Israel Chemicals (ICL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Schroder Investment Management Group boosted its position in shares of Israel Chemicals Ltd (NYSE:ICL) by 43.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 655,043 shares of the basic materials company’s stock after acquiring an additional 199,511 shares during the period. Schroder Investment Management Group owned approximately 0.05% of Israel Chemicals worth $10,939,000 at the end of the most recent quarter.
- [By Stephan Byrd]
Itasca Capital Ltd (CVE:ICL) Director Richard Michael Powell bought 25,000 shares of the company’s stock in a transaction on Monday, August 13th. The shares were bought at an average cost of C$0.57 per share, for a total transaction of C$14,250.00.
Top 10 Blue Chip Stocks To Invest In Right Now: Cott Corporation(COT)
Advisors’ Opinion:
- [By Shane Hupp]
Get a free copy of the Zacks research report on Cott (COT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
Cott Corp (NYSE:COT) (TSE:BCB) Director Steven P. Stanbrook purchased 13,500 shares of the company’s stock in a transaction dated Tuesday, February 26th. The stock was purchased at an average price of $14.77 per share, with a total value of $199,395.00. Following the transaction, the director now owns 13,500 shares of the company’s stock, valued at $199,395. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
- [By Logan Wallace]
GSA Capital Partners LLP grew its holdings in Cott Corp (NYSE:COT) (TSE:BCB) by 185.1% during the 2nd quarter, Holdings Channel reports. The firm owned 152,168 shares of the company’s stock after purchasing an additional 98,796 shares during the quarter. GSA Capital Partners LLP’s holdings in Cott were worth $2,518,000 at the end of the most recent reporting period.
- [By Joseph Griffin]
Cott (NYSE:COT) (TSE:BCB) was upgraded by analysts at Jefferies Group from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, MarketBeat reports. The firm currently has a $17.00 price objective on the stock. Jefferies Group’s price target indicates a potential upside of 6.25% from the stock’s previous close. Jefferies Group also issued estimates for Cott’s Q2 2018 earnings at $0.06 EPS, Q3 2018 earnings at $0.14 EPS, Q4 2018 earnings at $0.01 EPS and FY2020 earnings at $0.38 EPS.
- [By Stephan Byrd]
Cott (NYSE:COT) (TSE:BCB) last announced its quarterly earnings results on Thursday, May 3rd. The company reported ($0.02) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.02). Cott had a net margin of 14.54% and a return on equity of 1.79%. The firm had revenue of $560.80 million for the quarter, compared to analyst estimates of $563.81 million. During the same quarter in the previous year, the firm posted ($0.07) earnings per share. The business’s revenue was up 4.5% on a year-over-year basis. sell-side analysts anticipate that Cott will post 0.21 earnings per share for the current fiscal year.
Top 10 Blue Chip Stocks To Invest In Right Now: Cross Country Healthcare, Inc.(CCRN)
Advisors’ Opinion:
- [By Joseph Griffin]
Cross Country Healthcare, Inc. (NASDAQ:CCRN) – Research analysts at SunTrust Banks dropped their Q1 2019 earnings estimates for Cross Country Healthcare in a report issued on Tuesday, February 19th. SunTrust Banks analyst T. Sommer now expects that the business services provider will post earnings per share of ($0.01) for the quarter, down from their prior forecast of $0.01. SunTrust Banks has a “Hold” rating on the stock. SunTrust Banks also issued estimates for Cross Country Healthcare’s Q2 2019 earnings at $0.01 EPS, Q1 2020 earnings at ($0.01) EPS and Q2 2020 earnings at $0.04 EPS.
- [By ]
Activist investor Glenn Welling of Engaged Capital LLC, the insurgent investor agitating for changes at TiVo, Rent-a-Center, on Tuesday, May 15, revealed new positions in Aratana Therapeutics Inc. (PETX) , Cross Country Healthcare Inc. (CCRN) and Finisar Corp. (FNSR)
- [By Joseph Griffin]
Cross Country Healthcare, Inc. (NASDAQ:CCRN) has received an average recommendation of “Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $14.00.
- [By Ethan Ryder]
Cross Country Healthcare (NASDAQ:CCRN) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cross Country Healthcare, Inc. is a national leader in providing innovative healthcare workforce solutions and staffing services. Their diverse client base includes both clinical and nonclinical settings, servicing acute care hospitals, physician practice groups, outpatient and ambulatory-care centers, nursing facilities, both public schools and charter schools, rehabilitation and sports medicine clinics, government facilities, and homecare. They are able to place clinicians on travel and per diem assignments, local short-term contracts and permanent positions. They are a market leader in providing flexible workforce management solutions, which include managed services programs (MSP), internal resource pool consulting and development, electronic medical record (EMR) transition staffing, recruitment process outsourcing, predictive modeling and other outsourcing and consultative services. “
- [By Lisa Levin]
Losers
Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
Arcadia Biosciences, Inc. (N
Top 10 Blue Chip Stocks To Invest In Right Now: AmerisourceBergen Corporation (Holding Co)(ABC)
Advisors’ Opinion:
- [By Motley Fool Transcribing]
AmerisourceBergen (NYSE:ABC) Q1 2019 Earnings Conference CallJan. 31, 2019 8:30 a.m. ET
Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:Operator
- [By Ethan Ryder]
COPYRIGHT VIOLATION NOTICE: “Sivik Global Healthcare LLC Has $744,000 Holdings in AmerisourceBergen Corp. (ABC)” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4194514/sivik-global-healthcare-llc-has-744000-holdings-in-amerisourcebergen-corp-abc.html.
- [By Stephan Byrd]
Golub Group LLC increased its holdings in shares of AmerisourceBergen Corp. (NYSE:ABC) by 11.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,519 shares of the company’s stock after purchasing an additional 1,691 shares during the quarter. Golub Group LLC’s holdings in AmerisourceBergen were worth $1,229,000 at the end of the most recent reporting period.
- [By Ethan Ryder]
Peel Hunt restated their buy rating on shares of Abcam (LON:ABC) in a report issued on Monday morning.
A number of other equities research analysts have also commented on ABC. Numis Securities upgraded Abcam to an add rating and set a GBX 1,340 ($17.51) target price on the stock in a research report on Tuesday, January 8th. JPMorgan Chase & Co. reiterated a neutral rating on shares of Abcam in a research report on Thursday, January 10th. Finally, Berenberg Bank reiterated a buy rating and issued a GBX 1,640 ($21.43) target price on shares of Abcam in a research report on Tuesday, January 8th.
- [By Ethan Ryder]
Alphabit (CURRENCY:ABC) traded down 14.2% against the US dollar during the 24-hour period ending at 19:00 PM Eastern on April 11th. Alphabit has a market cap of $0.00 and approximately $999.00 worth of Alphabit was traded on exchanges in the last 24 hours. One Alphabit token can now be purchased for about $33.91 or 0.00489408 BTC on cryptocurrency exchanges including C-CEX and Cryptopia. In the last week, Alphabit has traded up 2.4% against the US dollar.
- [By Logan Wallace]
AmerisourceBergen (NYSE: ABC) and Trxade Group (OTCMKTS:TRXD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.
Top 10 Blue Chip Stocks To Invest In Right Now: Monsanto Company(MON)
Advisors’ Opinion:
- [By Logan Wallace]
Global X Management Co. LLC trimmed its stake in shares of Monsanto (NYSE:MON) by 6.8% during the first quarter, HoldingsChannel.com reports. The fund owned 11,141 shares of the basic materials company’s stock after selling 818 shares during the period. Global X Management Co. LLC’s holdings in Monsanto were worth $1,300,000 as of its most recent SEC filing.
- [By Matthew Frankel]
Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B), the conglomerate led by billionaire investor Warren Buffett, is officially receiving a nice windfall of cash. The acquisition of agricultural giant Monsanto (NYSE:MON) by Germany’s Bayer (NASDAQOTH:BAYRY) in an all-cash deal is putting more than $2.4 billion back into Berkshire’s coffers.
- [By ]
What Buffett Is Buying Now…
And speaking of the Oracle of Omaha, recent reports on insider activity included news that Buffett recently increased his stake in high-tech farming giant, Monsanto (NYSE: MON). - [By ]
In addition, Corvex Management’s Keith Meister reported owning new significant stakes in Intercontinental Exchange Inc. ( (ICE) ), Microsoft Corp. (MSFT) , Monsanto Co. (MON) , Qualcomm Inc. (QCOM) , Salesforce.com Inc. (CRM) and Servicenow Inc. (NOW)
Top 10 Blue Chip Stocks To Invest In Right Now: Principal Financial Group Inc(PFG)
Advisors’ Opinion:
- [By Joseph Griffin]
Sawtooth Solutions LLC bought a new position in Principal Financial Group Inc (NYSE:PFG) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 17,428 shares of the financial services provider’s stock, valued at approximately $922,000.
- [By Logan Wallace]
ING Groep NV boosted its stake in Principal Financial Group Inc (NYSE:PFG) by 7.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 27,524 shares of the financial services provider’s stock after purchasing an additional 1,991 shares during the period. ING Groep NV’s holdings in Principal Financial Group were worth $1,676,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
- [By Max Byerly]
Shore Capital reissued their hold rating on shares of Provident Financial (LON:PFG) in a report issued on Thursday.
PFG has been the subject of several other reports. Liberum Capital reissued a sell rating and set a GBX 483 ($6.48) price objective on shares of Provident Financial in a research note on Monday, February 26th. Peel Hunt reissued a hold rating and set a GBX 870 ($11.67) price objective on shares of Provident Financial in a research note on Tuesday, February 27th. JPMorgan Chase & Co. reduced their price objective on Provident Financial from GBX 1,100 ($14.76) to GBX 750 ($10.06) and set a neutral rating for the company in a research note on Thursday, May 10th. Barclays reissued an underweight rating and set a GBX 584 ($7.84) price objective on shares of Provident Financial in a research note on Wednesday, January 31st. Finally, Societe Generale lowered Provident Financial to a hold rating and set a GBX 1,050 ($14.09) price objective for the company. in a research note on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company’s stock. Provident Financial presently has a consensus rating of Hold and a consensus price target of GBX 1,190.14 ($15.97).
- [By Logan Wallace]
Provident Financial plc (LON:PFG) has received a consensus recommendation of “Hold” from the fifteen research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is GBX 1,244.33 ($16.57).
- [By ]
Principal Financial Group (Nasdaq: PFG) is a diversified financial firm with $540 billion in assets under management and leadership in retirement investment products, fund investments and life insurance. The company missed Q2 earnings on non-recurring items which sent the shares skidding lower but core business in retirement income solutions and insurance remains solid.
- [By Logan Wallace]
Get a free copy of the Zacks research report on Principal Financial Group (PFG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 10 Blue Chip Stocks To Invest In Right Now: PJT Partners Inc.(PJT)
Advisors’ Opinion:
- [By Shane Hupp]
PJT Partners (NYSE:PJT) and MAN GRP PLC/ADR (OTCMKTS:MNGPY) are both finance companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on PJT Partners (PJT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com